For the Inventor, By the Inventor

Enter assignee name

Province, China

Jiangsu Hengrui Medicine Company Ltd.

USPTO Granted Patents = 159

CIPO Patents = 13

EPO Patents = 67

Forward Citations = 153

Loading Chart...

Loading Chart...

289 inventors (with patents filed for the assignee):

Weikang Tao (43 out of 49 patents)

Piaoyang Sun (35 out of 42 patents)

Lianshan Zhang (28 out of 29 patents)

4. Feng He (23 out of 79 patents)

5. Qiyue Hu (20 out of 20 patents)

6. Qing Dong (15 out of 67 patents)

7. Guoqing Cao (14 out of 15 patents)

8. Guaili Wu (14 out of 15 patents)

9. Fanglong Yang (14 out of 20 patents)

10. Yun Lu (12 out of 12 patents)

11. Peng Cho Tang (10 out of 21 patents)

12. Xin Ye (9 out of 14 patents)

13. Fei Li (9 out of 56 patents)

14. Xiangdong Qu (8 out of 8 patents)

15. Xiaohui Gao (8 out of 8 patents)

Core Competencies:

Echinocandin Analogues

Anti-PD-1 Antibody

VEGFR Inhibitor

Thymic Stromal Lymphopoietin

PARP Inhibitors

Benzimidazole Derivatives

IL-5 Antibody

TIGIT Antibody

Tyrosine Kinase Inhibitor

Fusion Proteins

JAK Kinase Inhibitors

Indazole Derivatives

159 patents: Sort by Forward Citations

1. 12466856 - Echinocandin analogues and preparation method therefor (2025-11-11),

2. 12435144 - Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers (2025-10-07),

3. 12428482 - Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof (2025-09-30),

4. 12428478 - Anti-Claudin 18.2 antibody and application thereof (2025-09-30),

5. 12428428 - Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine (2025-09-30),

6. 12428396 - Fused pyridine ring derivative, preparation method therefor, and pharmaceutical use thereof (2025-09-30),

7. 12421260 - Neurokinin-1 antagonist (2025-09-23),

8. 12404323 - Antibody capable of binding to thymic stromal lymphopoietin and use thereof (2025-09-02),

9. 12325741 - Anti-Aβ antibodies and antigen-binding fragments thereof (2025-06-10),

10. 12325696 - Indazole derivative, preparation method therefor, and pharmaceutical application thereof (2025-06-10),

11. 12318385 - Pharmaceutical composition comprising PARP inhibitors (2025-06-03),

12. 12269823 - Crystal form of pyridopyrimidine derivative and preparation method thereof (2025-04-08),

13. 12258405 - CD3 antibody and pharmaceutical use thereof (2025-03-25),

14. 12258394 - IL-5 antibody, antigen binding fragment thereof, and medical application therefor (2025-03-25),

15. 12240904 - Use of anti-PD-1 antibody in combination with famitinib in preparation of drug for treating tumors (2025-03-04),

Jiangsu Hengrui Medicine Company Ltd. is a leading pharmaceutical company based in China. With a focus on research, development, production, and sales of innovative medicines, Hengrui strives to improve the health and well-being of individuals globally. The company offers a broad range of high-quality products in various therapeutic areas, including oncology, anesthesia, cardiovascular diseases, and more. Hengrui Medicine is dedicated to fostering partnerships, enhancing medical advancements, and delivering effective solutions to patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

159 Patents

#2 in Province

#198 in China

#5,050 in the World

Province, China

Jiangsu Hengrui Medicine Company Ltd.

Forward Citations = 153

289 inventors:

Weikang Tao (43 out of 49 patents)

Piaoyang Sun (35 out of 42 patents)

Lianshan Zhang (28 out of 29 patents)

4. Feng He (23 out of 79 patents)

5. Qiyue Hu (20 out of 20 patents)

Please report any incorrect information to support@idiyas.com

Loading…